September 26, 2016 — A new analysis of Veteran’s Affairs Central Cancer Registry records demonstrates a clear positive impact of increased stereotactic body radiation therapy (SBRT) use for stage 1 non-small cell lung cancer (NSCLC) patients.

September 26, 2016 — IBA (Ion Beam Applications S.A.) and Philips announced that they are stepping up their combined efforts in adaptive proton therapy planning through a new long-term collaboration agreement.

September 26, 2016 — For men with intermediate-risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment and conventional treatment, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Stereotactic radiosurgery (SRS) for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates compared to observation alone following surgical resection. These conclusions were drawn from research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

September 26, 2016 — At the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 25-28 in Boston, Elekta will showcase its HD Dynamic Radiosurgery that leverages the core strengths of Versa HD linear accelerator and Monaco treatment planning system.

New research suggests hypofractionated radiation therapy (RT) offers similar results to standard RT in several key areas for stage II and III non-small cell lung cancer (NSCLC) patients who are unable to receive standard treatments of surgery or chemoradiation (CRT). Hypofractionated RT showed similar results in overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times.

September 23, 2016 — IBA unveiled its new platform, 'Leading the PATh', which gathers the leading experts in the field of proton therapy all in one place. It is anticipated that 'Leading the PATh' will enable the worldwide medical community to shape the most efficient proton adaptive therapy (PATh), a proton therapy process which improves the accuracy of what is considered to be the most precise cancer treatment available today.

ZDi Solutions LLC announced that it will soon market its Z-System patient positioning devices to proton therapy and conventional radiation therapy facilities in the United States, with plans to collaborate worldwide. The system is comprised of the Z-Box, Z-Square and Z-Tilt. The team from ZDi will be attending the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston Sept. 25-28 to demonstrate the technology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now